Dynamic Technology Lab Private Ltd Acquires 14,468 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Dynamic Technology Lab Private Ltd lifted its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 309.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,150 shares of the company's stock after purchasing an additional 14,468 shares during the quarter. Dynamic Technology Lab Private Ltd's holdings in Amphastar Pharmaceuticals were worth $711,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Pacer Advisors Inc. lifted its position in Amphastar Pharmaceuticals by 51,977.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after purchasing an additional 1,347,775 shares during the period. Boston Trust Walden Corp raised its position in Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock worth $36,347,000 after acquiring an additional 439,281 shares in the last quarter. Boston Partners acquired a new stake in Amphastar Pharmaceuticals in the 4th quarter valued at about $15,778,000. Wealthfront Advisers LLC bought a new position in shares of Amphastar Pharmaceuticals during the 4th quarter valued at about $9,268,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $3,450,000. Institutional investors own 65.09% of the company's stock.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 27.10% of the stock is owned by company insiders.

Remove Ads

Amphastar Pharmaceuticals Stock Up 1.0 %

Amphastar Pharmaceuticals stock traded up $0.23 during mid-day trading on Friday, hitting $23.75. 145,024 shares of the company's stock were exchanged, compared to its average volume of 455,261. Amphastar Pharmaceuticals, Inc. has a 1-year low of $22.00 and a 1-year high of $53.96. The stock has a 50 day moving average of $28.86 and a two-hundred day moving average of $38.29. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The stock has a market cap of $1.13 billion, a P/E ratio of 7.90, a P/E/G ratio of 2.19 and a beta of 0.79.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday. Piper Sandler cut their target price on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.